ONC_OUT_1 [2025-04-11 08:11:25 -0400] 3630 Bytes | 992 tokens | Cum: 992 tkns (12.40% of 8k)
==========================================================================

We need a winner today and it's already 8:11:23 AM on Fri Apr 11, 2025 -0400 ... So let's find out if BeiGene (ONC) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 229.9000 up from 208.3100. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: BeiGene (ONC)
IPO: 2016-02-03 (9 Years Ago)
Market Cap: $22,439,029,464
Shares Outstanding: 1,282,360,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

Here’s the first list of news for BeiGene:

C1 - Apr-03-25 05:54PM - ImmunityBio: Taking Care Of Business
C2 - Apr-03-25 05:54PM 12:37PM - BeiGene halts ociperlimab amid poor Phase III trial predictions
C3 - Apr-03-25 05:54PM 06:00AM - BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
C4 - Mar-31-25 06:00AM - BeiGene Receives Positive CHMP Opinion for TEVIMBRA as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
C5 - Mar-18-25 07:45AM - EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
C6 - Mar-06-25 11:12AM - Q4 2024 Zymeworks Inc Earnings Call
C7 - Mar-05-25 04:54AM - FDA approves BeiGenes Tevimbra plus chemo for oesophageal cancer
C8 - Mar-04-25 06:00AM - TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: BeiGene (ONC).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
At the end, you'll be prompted to return these data pairs:

1) BRIEF_SUMMARY[] -- Write a brief summary
2) MARKET_SCORE[] -- Assign a Market Score
3) PRICE_TARGET[] -- Set a price target
4) AI_RPT_HEADLINE[] -- Generate a headline for the article
5) SQUEEZE_POTENTIAL[] -- Potential for this stock to become an active short squeeze play
6) TAGS[] -- 1 to 4 words for SEO tags
7) STOCK_TYPE[] -- Describe the type of investor style suited to this stock
8) PRIMARY_CATALYST[] -- What you believe caused this stock to move today
9) SENTIMENT[] -- Mkt sentiment of the opportunity
10) IMPROVEMENT_SUGGESTION[] -- What can we do better
11) ETHICAL_RATING[] -- Rate alignment with long-term shareholder interests

Restrict the next response to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

ONC_OUT_3 [2025-04-11 08:11:25 -0400] 903 Bytes | 284 tokens | Cum: 1278 tkns (15.97% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-10T20:01:11Z - Forecasting The Future: 4 Analyst Projections For BeiGene - BeiGene (NASDAQ:ONC)...
A2 - 2025-04-10T09:44:44Z - Beigene (NASDAQ:ONC) Upgraded by Royal Bank of Canada to Moderate Buy Rating...
A3 - 2025-04-10T09:44:44Z - Beigene (NASDAQ:ONC) Raised to Moderate Buy at Royal Bank of Canada...
A4 - 2025-04-10T01:49:17Z - Beigene (NASDAQ:ONC) Stock Price Down 7.7% - What's Next?...
A5 - 2025-04-08T04:42:49Z - BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ONC_OUT_5 [2025-04-11 08:11:28 -0400] 1098 Bytes | 352 tokens | Cum: 1632 tkns (20.40% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Forecasting The Future: 4 Analyst Projections For BeiGene - BeiGene (NASDAQ:ONC)**Date: 2025-04-10Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/analyst-ratings/25/04/44750293/forecasting-the-future-4-analyst-projections-for-beigeneBeiGene ONC underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 2 0 0 0 3M Ago 0 0 0 0 0

Analysts have set 12-month price targets for BeiGene, revealing an average target of $330.25, a high estimate of $348.00, and a low estimate of

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ONC_OUT_7 [2025-04-11 08:11:36 -0400] 1098 Bytes | 278 tokens | Cum: 1985 tkns (24.81% of 8k)
==========================================================================

Showing A1 (chunk 2 of 7): $312.00. This current average reflects an increase of 10.7% from the previous average price target of $298.33.

Diving into Analyst Ratings: An In-Depth Exploration

The perception of BeiGene by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

| Analyst | Analyst Firm | Action Taken | Rating |Current Price Target| Prior Price Target | |--------------------|------------------------|---------------|-----------------|--------------------|--------------------| |Michael Schmidt |Guggenheim |Maintains |Buy | $348.00|$348.00 | |Greg Renza |RBC Capital |Announces |Outperform | $312.00|- | |Tony Ren |Macquarie |Raises |Outperform | $313.00|$259.00 | |Matthew Carletti |Citizens Capital Markets|Raises |Market Outperform| $348.00|$288.00 |

Key Insights: Action Taken: An

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ONC_OUT_9 [2025-04-11 08:11:38 -0400] 1143 Bytes | 335 tokens | Cum: 2603 tkns (32.54% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-04-03T15:19:58Z - BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
B2 - 2025-03-04T13:37:25Z - China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
B3 - 2025-03-03T18:00:00Z - Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
B4 - 2025-02-25T11:00:00Z - Zymeworks Announces Participation in Upcoming Investor Conferences
B5 - 2025-02-23T15:05:30Z - Alibaba, Super Micro Computer And XPeng Are Among Top 10 Large Cap Gainers Last Week (Feb 17-Feb 21): Are The Others In Your Portfolio?
B6 - 2025-02-13T11:00:00Z - Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ONC_OUT_11 [2025-04-11 08:11:43 -0400] 683 Bytes | 187 tokens | Cum: 2792 tkns (34.90% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/general/biotech/25/04/44630279/beigene-discontinues-lung-cancer-drug-study-after-interim-data-showed-limited-survival-benefitBeiGene has discontinued its ociperlimab lung cancer trial after an interim analysis showed the drug was unlikely to meet the overall survival endpoint when compared to Merck's Keytruda.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ONC_OUT_13 [2025-04-11 08:11:44 -0400] 1111 Bytes | 285 tokens | Cum: 3187 tkns (39.84% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S2 - 2025-02-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and related notes appeari...

S3 - 2025-01-13 8-K Item 7.01 Regulation FD Disclosure.

On January 13, 2025, BeiGene, Ltd. (the Company) participated in the 43rd Annual J.P. Morgan Healthcare Conference and announced that the Company expects to achieve positive operating income for full year 2025 pursuant to U.S. generally accep...

S4 - 2024-12-10 8-K Item 1.01. Entry into a Material Definitive Agrmt.

On December 9, 2024 (the Signing Date), a facility agreement (the Facility Agrmt) was entered into by and between BeiGene, Ltd. (the Company), as the borrower, and China Merchants Bank Co., Ltd., as the lender (the Lend...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ONC_OUT_15 [2025-04-11 08:11:45 -0400] 1098 Bytes | 222 tokens | Cum: 3411 tkns (42.64% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. In addition to historical information, this discussion and analysis contains forwardlooking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forwardlooking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this report, including those set forth under Part IItem 1ARisk Factors and under ForwardLooking Statements and Market Data in this Annual Report.

Non-GAAP Financial Measures

We provide ce

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ONC_OUT_17 [2025-04-11 08:11:48 -0400] 1098 Bytes | 232 tokens | Cum: 3645 tkns (45.56% of 8k)
==========================================================================

Showing S2 (chunk 2 of 6): rtain financial measures that are not defined under accounting principals generally accepted in the United States of America (GAAP), commonly referred to as non-GAAP financial measures, including Adjusted Operating Expenses and Adjusted Income (Loss) from Operations and certain other non-GAAP measures, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on our operating performance. Adjustments to our GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. We maintain an established non-GAAP policy that guides the determination of what items may be excluded in non-GAAP financial measur

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ONC_OUT_19 [2025-04-11 08:11:54 -0400] 4466 Bytes | 1124 tokens | Cum: 4771 tkns (59.64% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+------------------------+-------------------------+-----------------------+
| Volume: 930,392 | Perf Month: -16.62% | Option/Short: Yes / Yes | Sales Y/Y TTM: 54.96% |
+---------------------+------------------------+-------------------------+-----------------------+
| Avg Volume: 500.58K | Perf Quarter: 17.11% | Short Float: 1.63% | ROE: -18.77% |
+---------------------+------------------------+-------------------------+-----------------------+
| Rel Volume: 1.90 | Index: - | Short Ratio: 3.19 | ROI: -18.20% |
+---------------------+------------------------+-------------------------+-----------------------+
| RSI (14): 30.79 | Market Cap: 20.60B | Short Interest: 1.60M | Sales Surprise: 7.94% |
+---------------------+------------------------+-------------------------+-----------------------+
| ATR (14): 13.51 | Shs Outstand: 98.87M | Beta: 0.47 | EPS Surprise: -41.28% |
+---------------------+------------------------+-------------------------+-----------------------+
| SMA20: -16.95% | Shs Float: 97.83M | Sales Q/Q: 77.78% | P/E: - |
+---------------------+------------------------+-------------------------+-----------------------+
| SMA50: -15.18% | Inst Own: 40.42% | Sales past 5Y: 80.39% | Earnings: Feb 27 BMO |
+---------------------+------------------------+-------------------------+-----------------------+
| SMA200: 1.37% | Insider Own: 1.05% | Employees: 11000 | |
+---------------------+------------------------+-------------------------+-----------------------+
| Perf Week: -21.19% | Insider Trans: -95.12% | Debt/Eq: 0.32 | |
+---------------------+------------------------+-------------------------+-----------------------+

The next section covers any insider trading if available.

Inside Trans: BeiGene, Ltd. (ONC) by BAKER BROS. ADVISORS LP (Unknown Title) on 2025-02-28
- American Depositary Shares: 60851 shares at $260 (I)
- American Depositary Shares: 671976 shares at $260 (I)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 208.31
Average Volume: 522458.41
30-Day High: 274.78
30-Day Low: 206.32
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of {co_name} ({ticker}).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings.

2) MARKET_SCORE[]
Estimate a number between 1–100 based on the likelihood of an upward price move.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a new price based on your analysis.
For example, if you expect a 50% increase, say: PRICE_TARGET[7.80]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing the report.

5) SQUEEZE_POTENTIAL[] Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose one: growth, value, turnaround, hype, squeeze, etc.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis.

11) ETHICAL_RATING[]
Rate this company’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the 11 questions.
Respond with all 10 pairs. Take your best guess if you have to, but don't leave any items blank.

ONC_IN_21 [2025-04-11 08:11:55 -0400] 126 Bytes | 29 tokens | Cum: 5029 tkns (62.86% of 8k)
==========================================================================

====================================
[2025-04-11 08:11:55] # Analysis Completed
Elapsed Time: 31.39 seconds